Mr. Mohamed Eltokhy | Cancer Biology | Best Researcher Award

MSc, TTUHSC, United States

Mohamed Ashraf Eltokhy is a dedicated researcher and Assistant Lecturer at Texas Tech University Health Science Center (TTUHSC) in Abilene, Texas, where he’s contributing to the development of innovative cancer therapies. With an academic background in pharmaceutical sciences, he has experience in both clinical and academic settings, focusing on immunotherapeutic and biotechnological approaches to cancer treatment. Passionate about improving cancer therapies, he leads impactful research initiatives, aiming to advance safer, more effective treatment options for patients.

Profile

Orcid

Google Scholar

Education 🎓

Mohamed holds a Bachelor’s degree in Pharmaceutical Science from Misr International University in Cairo, graduating with high honors (GPA 3.95). He further pursued a Master of Science in Microbiology and Immunology at Al-Azhar University. Currently, he’s a PhD candidate at TTUHSC, studying in the Department of Immunotherapeutic and Biotechnology. His academic journey is marked by consistent excellence and a strong commitment to cancer research, achieving a cGPA of 3.948.

Experience 🧑‍🏫

Mohamed’s diverse experience spans research, academia, and leadership. As the CEO of Neopurpose Therapeutics, he drives strategic decisions, investor relations, and competitor analysis. In academia, he has held positions such as Assistant Lecturer at Misr International University, where he taught microbiology, immunology, and biochemistry. His research experience includes a guest researcher role at Leiden University and involvement in innovative cancer drug studies at TTUHSC, demonstrating his commitment to advancing scientific knowledge and application in cancer therapeutics.

Research Interest 🔬

Mohamed’s research focuses on developing novel anti-cancer agents and bioprinted tumor-on-chip models for drug discovery. His work includes in vitro screening of new compounds, mechanistic studies, and safety evaluations, as well as in vivo research to establish efficacy and safety. His overarching goal is to create more personalized cancer treatment options and to understand the molecular mechanisms involved in cancer progression and treatment.

Awards & Recognition 🏆

Throughout his career, Mohamed has received multiple awards, including the Texas Tech Accelerator Program Award in 2024, and a prestigious poster presentation at the American Association of Cancer Research (AACR). His excellence in academia was recognized with awards for valuable contributions at MIU’s senior conferences and honors for outstanding academic performance in Microbiology and Immunology.

Publications Top Notes 📑

1. Dec 2021: Eltokhy, M. A., Saad, B. T., Eltayeb, W. N., Yahia, I. S., Aboshanab, K. M., & Ashour, M. S. E. “Exploring the Nature of the Antimicrobial Metabolites Produced by Paenibacillus ehimensis Soil Isolate MZ921932 Using a Metagenomic Nanopore Sequencing Coupled with LC-Mass Analysis,” Journal of Antibiotics (MDPI)..
2. Nov 2021: Eltokhy, M. A., Saad, B. T., Eltayeb, W. N., El-Ansary, M. R., Aboshanab, K. M., & Ashour, M. S. E. “A metagenomic nanopore sequence analysis combined with conventional screening and spectroscopic methods for deciphering the antimicrobial metabolites produced by Alcaligenes faecalis soil isolate MZ921504,” Journal of Antibiotics (MDPI)..
3. Sep 2020: Eassa, H. A., Eltokhy, M. A., Fayyaz, H. A., Khalifa, M. K. A., Shawky, S., Helal, N. A., & Nounou, M. I. “Current Topical Strategies for Skin-Aging and Inflammaging Treatment: Science versus Fiction,” Europe PMC..
4. May 2019: Helal, N. A., Elnoweam, O., Eassa, H. A., Amer, A. M., Eltokhy, M. A., Helal, M. A., Fayyaz, H. A., & Nounou, M. I. “Integrated Continuous Manufacturing in Pharmaceutical Industry: Current Evolutionary Steps Towards Revolutionary Future,” Pharmaceutical Patent Analyst (Clarivate Analytics)..
5. Jan 2019: Helal, N. A., Eassa, H. A., Amer, A. M., Eltokhy, M. A., Edafiogho, I., & Nounou, M. I. “Nutraceuticals’ novel formulations: the good, the bad, the unknown and patents involved,” Recent Patents on Drug Delivery & Formulation (Bentham Science)..